Related Experiment Videos
Tumor cell-targeting by phage-displayed peptides.
Ulla B Rasmussen1, Valerie Schreiber, Huguette Schultz
1Department of Molecular and Cellular Biology, Transgene, SA, 11 rue de Molsheim, F-67082 Strasbourg, France. rasmussen@transgene.fr
Cancer Gene Therapy
|June 26, 2002
Summary
Researchers developed cancer cell-specific phages to identify potential colorectal cancer biomarkers. The selected phage displayed high binding efficiency to WiDr cells, leading to a peptide that may aid in developing new cancer diagnostics and therapies.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Phage display technology enables the selection of peptides that bind to specific targets.
- Identifying cancer-specific biomarkers is crucial for developing targeted therapies and diagnostics.
Purpose of the Study:
- To isolate and characterize cancer cell-specific phages and their corresponding peptides.
- To evaluate the binding efficiency and specificity of selected phages and peptides against human cancer cell lines.
Main Methods:
- Complex peptide display phage libraries were screened against cultured human cancer cells.
- Selection involved multiple rounds of subtraction and enrichment on the human colorectal WiDr cell line.
- Binding efficiency was quantified by comparing phage binding to WiDr cells versus other cancer cell lines and wild-type M13 phage.
Main Results:
- A selected phage exhibited over 1000-fold higher binding efficiency to WiDr cells compared to five other cancer cell lines.
- The phage also showed 50-fold higher binding to a human breast cancer cell line.
- The peptide HEWSYLAPYPWF, derived from the phage sequence, effectively competed for WiDr cell binding, confirming its specificity.
Conclusions:
- The identified peptide demonstrates high specificity for colorectal cancer cells, independent of phage display.
- This peptide holds potential for developing targeted gene transfer vectors, diagnostic tools, and prognostic markers for colorectal cancer.